Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
Сигналинг интерлейкина-6 и терапия анти-интерлейкином-6 при сердечно-сосудистых заболеваниях
2021-05-17
SCID: 54.1/fvqt447c
Discuss with AI
Atherosclerotic cardiovascular diseaseIL-6 inhibitionInterleukin-6 signalingNLRP3 inflammasomeZiltivekimab
Figures from the paper
Abstract (AI)
IL (interleukin)-6 is a pivotal cytokine of innate immunity, which enacts a broad set of physiological functions traditionally associated with host defense, immune cell regulation, proliferation, and differentiation. Following recognition of innate immune pathways leading from the NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) inflammasome to IL-1 to IL-6 and on to the hepatically derived clinical biomarker CRP (C-reactive protein), an expanding literature has led to understanding of the proatherogenic role for IL-6 in cardiovascular disease and thus the potential for IL-6 inhibition as a novel method for vascular protection. In this review, we provide an overview of the mechanisms by which IL-6 signaling occurs and how that impacts upon pharmacological inhibition; describe murine models of IL-6 and atherogenesis; summarize human epidemiological data outlining the utility of IL-6 as a biomarker of vascular risk; outline genetic data suggesting a causal role for IL-6 in systemic atherothrombosis and aneurysm formation; and then detail the potential role of IL-6 inhibition in stable coronary disease, acute coronary syndromes, heart failure, and the atherothrombotic complications associated with chronic kidney disease and end-stage renal failure. Finally, we review anti-inflammatory and antithrombotic findings for ziltivekimab, a novel IL-6 ligand inhibitor being developed specifically for use in atherosclerotic disease and poised to be tested formally in a large-scale cardiovascular outcomes trial focused on individuals with chronic kidney disease and elevated levels of CRP, a population at high residual atherothrombotic risk, high residual inflammatory risk, and considerable unmet clinical need.
Key Findings
1
A large cardiovascular outcomes trial is planned to evaluate ziltivekimab in patients with chronic kidney disease, elevated CRP, and substantial residual inflammatory and atherothrombotic risk.
2
Human epidemiological and genetic data indicate that IL-6 is associated with vascular risk and may causally contribute to systemic atherothrombosis and aneurysm formation.
3
IL-6 inhibition is being investigated across stable coronary disease, acute coronary syndromes, heart failure, and atherothrombotic complications of chronic kidney disease.
4
IL-6 is positioned as a central mediator linking innate immune activation through the NLRP3–IL-1–IL-6 pathway to hepatic CRP production and cardiovascular inflammation.
5
The reviewed evidence supports a proatherogenic role for IL-6 and suggests that IL-6 inhibition may provide vascular protection in cardiovascular disease.
6
Ziltivekimab, a novel IL-6 ligand inhibitor, shows anti-inflammatory and antithrombotic potential and is being developed for high-risk patients with chronic kidney disease and elevated CRP.
Research Object
IL-6 signaling and IL-6 inhibition in cardiovascular disease, including atherosclerosis and atherothrombotic complications
Research Subject
The mechanisms, vascular-risk associations, therapeutic effects, and clinical potential of IL-6 signaling and anti-IL-6 therapies
Publication Details
Publication Date
2021-05-17
Journal
Publisher
ISSN
Cited by
696
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease2017
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction2019
Colchicine in Patients with Chronic Coronary Disease2020
Interleukin‐1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST‐Segment–Elevation Myocardial Infarction2020